News

UK Biotech & Life Sciences News

Follow the latest UK life sciences company news, including biotech funding rounds, pharma partnerships, product launches, clinical updates, infrastructure projects and commercial announcements.

Latest updates
Showing 229–240 of 243 stories

Fortrea to Acquire Worldwide Clinical Trials' Early Phase Services for $45m

Fortrea has agreed to acquire Worldwide Clinical Trials' clinical pharmacology unit and bioanalytical laboratory operations for about $45m in cash, comprising a GLP bioanalytical laboratory in Austin, a 200-bed clinical pharmacology unit in San Antonio and a biospecimen storage site in Pflugerville, all in Texas. Worldwide says the sale will let it focus investment on its late-stage business in oncology, neuroscience, internal medicine and rare disease, and completion remains subject to regulatory and licence approvals.

Funding & Grants2 Sept 2026

Qkine Secures £1.6m Follow-On Investment

Qkine has secured £1.6 million in follow-on investment from CPI Enterprises, EverQuest Capital Partners, Parkwalk Advisors and EMV Capital, building on CPI Enterprises' initial backing in 2022. The funding will support Qkine's growth factors, cytokines and proteins for stem cell and cell therapy manufacturing, with the company planning to strengthen its leadership team, grow its US presence, scale GMP-grade manufacturing and expand R&D.

Redx Pharma appoints Mei-Lun Wang as chief medical officer

Redx Pharma has appointed Dr Mei-Lun Wang, a paediatric gastroenterologist with over 25 years of clinical and drug development experience, as chief medical officer. The appointment follows the addition of gastroenterologist Dr Bernard Coulie to Redx's board on 27 August 2026, further bolstering the company's gastroenterology expertise around lead candidate RXC008 for fibrostenotic Crohn's disease.

Foventa Therapeutics appoints CMO and CFO ahead of Series A

Foventa Therapeutics has appointed Dr Zaiba Malik as Chief Medical Officer and Julia Jones as Chief Financial Officer, ahead of a planned Series A round to take lead candidate FOV407 into a Phase IIb trial. Malik joins from Medpace, where she was Global Medical Director and Therapeutic Area Lead for Ophthalmology, while Jones has previously supported biotech fundraises including for Amphista Therapeutics and Congenica.

Renalytix signs multi-year Quest Diagnostics agreement

Renalytix has signed a multi-year agreement with Quest Diagnostics to expand US access to its kidneyintelX.dkd blood test, with availability through Quest's specimen collection and connectivity network targeted for early 2027. Renalytix will continue to run the assay at its New York laboratory and handle billing, while the deal also gives Quest an option to in-license the test after specified commercialisation milestones.

Exonate rebrands as Foventa Therapeutics

Exonate has renamed itself Foventa Therapeutics, marking its transition from a science-led discovery company into a patient-oriented, clinical-stage business. The company's lead candidate, FOV407, is a topical eye drop targeting the VEGF pathway for non-proliferative diabetic retinopathy, with a Phase IIb trial in preparation following a design validated through a Type C meeting with the FDA.

Resolution Therapeutics partners with Blood Centers of America for US access

Resolution Therapeutics has partnered with the Blood Centers of America to support US patient access to RTX001, its lead Regenerative Macrophage Therapy candidate for end-stage liver disease. The partnership underpins Resolution's pivotal clinical programme planned for 2027 and aims to let decompensated cirrhosis patients receive treatment locally rather than only at transplant centres.

Apollo Therapeutics and Imperial Report Encouraging Common Cold Vaccine Data

Apollo Therapeutics and Imperial College London have completed enrolment and dosing in a Phase 1 trial of APL-10456, a vaccine candidate targeting rhinovirus, the main cause of the common cold. Initial results from the 144-participant, placebo-controlled study showed a single dose was well tolerated and induced immune responses against all three major rhinovirus species; a second phase is underway with results expected by year-end.

hVIVO Acquires CRS Berlin, Expanding into Dermatology and Women's Health

hVIVO has acquired CRS Clinical Research Services Berlin GmbH, a Phase I/II clinical research unit with a contracted orderbook of approximately €10 million and a track record of 350 completed studies. The deal extends hVIVO's German network alongside its existing Mannheim and Kiel units, adding dermatology and women's health to its therapeutic range, and is expected to be immediately earnings accretive in FY26 under a nominal-upfront, earnout-based structure.